The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Liposome-based drug delivery in breast cancer treatment
Open accessAbstract
Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels. Liposomal anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs represent an integration of biological components capable of tumor recognition with delivery technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“Trastuzumab in combination with doxorubicin or epirubicin is highly efficacious but is associated with an extremely high frequency of cardiotoxicity [12].”
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Self-citationNeedham, D., Anyarambhatla, G., Kong, G., & Dewhirst, M. W. (2000) · PubMed · Cited by 746
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Self-citationGill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Self-citation
Cited by
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
The Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Small particles, big impacts: A review of the diverse applications of nanofluids
Taylor, R., Coulombe, S., Otanicar, T., Phelan, P., Gunawan, A., Lv, W., Rosengarten, G., Prasher, R., & Tyagi, H. (2013) · Journal of Applied Physics · doi:10.1063/1.4754271 · Cited by 759
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 657
Zylberberg, C., & Matosevic, S. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1177136 · Cited by 627
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles☆
WONG, H., BENDAYAN, R., RAUTH, A., LI, Y., & WU, X. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.008 · Cited by 578
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
Ahmed, F., Pakunlu, R. I., Brannan, A., Bates, F., Minko, T., & Discher, D. E. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.07.012 · Cited by 548
Molecular Imaging with Theranostic Nanoparticles
Jokerst, J. V., & Gambhir, S. S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200106e · Cited by 548
Nanoparticles: Emerging carriers for drug delivery
Mudshinge, S. R., Deore, A. B., Patil, S., & Bhalgat, C. M. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.04.001 · Cited by 543
Lipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging
Mulder, W. J. M., Strijkers, G. J., van Tilborg, G. A. F., Griffioen, A. W., & Nicolay, K. (2006) · NMR in Biomedicine · doi:10.1002/nbm.1011 · Cited by 535
Deng, Z. J., Morton, S. W., Ben-Akiva, E., Dreaden, E. C., Shopsowitz, K. E., & Hammond, P. T. (2013) · ACS Nano · doi:10.1021/nn4047925 · Cited by 516
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
Aghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M., & Aghebati‐Maleki, L. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29126 · Cited by 417
Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery
Zahin, N., Anwar, R., Tewari, D., Kabir, M. T., Sajid, A., Mathew, B., Uddin, M. S., Aleya, L., & Abdel-Daim, M. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-05211-0 · Cited by 371
Carbon nanotubes in cancer diagnosis and therapy
Ji, S.-R., Liu, C., Zhang, B., Yang, F., Xu, J., Long, J., Jin, C., Fu, D.-L., Ni, Q.-X., & Yu, X.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.02.004 · Cited by 338
Ahmed, F., Pakunlu, R. I., Srinivas, G., Brannan, A., Bates, F., Klein, M. L., Minko, T., & Discher, D. E. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050103u · Cited by 330
Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery
Lamichhane, N., Udayakumar, T., D’Souza, W., Simone II, C., Raghavan, S., Polf, J., & Mahmood, J. (2018) · Molecules · doi:10.3390/molecules23020288 · Cited by 303
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
Sustained-release from nanocarriers: a review
Natarajan, J. V., Nugraha, C., Ng, X. W., & Venkatraman, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.029 · Cited by 285
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
Jin, S., & Ye, K. (2007) · Biotechnology Progress · doi:10.1021/bp060348j · Cited by 283
Heister, E., Neves, V., Tîlmaciu, C., Lipert, K., Beltrán, V. S., Coley, H. M., Silva, S. R. P., & McFadden, J. (2009) · Carbon · doi:10.1016/j.carbon.2009.03.057 · Cited by 259
Jusu, S. M., Obayemi, J. D., Salifu, A. A., Nwazojie, C. C., Uzonwanne, V., Odusanya, O. S., & Soboyejo, W. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-71129-0 · Cited by 112
Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin
Dicko, A., Kwak, S., Frazier, A. A., Mayer, L. D., & Liboiron, B. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.02.014 · Cited by 87
Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., Wang, D., Guo, M., Yu, J., Zhao, C., & Feng, B. (2017) · Wound Repair and Regeneration · doi:10.1111/wrr.12520 · Cited by 54
Famta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01669-9 · Cited by 21
Metadata
- Authors
- Park, J. W.
- Venue
- Breast Cancer Research
- Published
- 2002-06
- Volume
- 4
- Issue
- 3
- Pages
- 95-9
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1492185019
- Cited by
- 469
- References
- 19
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.